Zervimesine is a Cognition Therapeutics Inc program in mild cognitive impairment and early Alzheimer's disease. Its next catalyst is a Readout in Q4 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Mild cognitive impairment and early Alzheimer's disease. Sponsor: Cognition Therapeutics Inc (CGTX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for Zervimesine is a Readout in Q4 2027.
No FDA decision for Zervimesine is in our archive yet.
In our records Zervimesine is under review or in development for Mild cognitive impairment and early Alzheimer's disease.
Cognition Therapeutics Inc (CGTX).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.